Centiva Capital’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-17,900
Closed -$184K 1740
2022
Q4
$184K Sell
17,900
-1,000
-5% -$17.6K 0.01% 1107
2022
Q3
$345K Buy
18,900
+17,000
+895% +$737K 0.01% 998
2022
Q2
$97K Sell
1,900
-5,000
-72% -$259K ﹤0.01% 1434
2022
Q1
$508K Sell
6,900
-900
-12% -$80.3K 0.01% 968
2021
Q4
$1.12M Buy
7,800
+6,910
+776% +$1.19M 0.02% 578
2021
Q3
$184K Sell
890
-8,110
-90% -$1.79M 0.01% 949
2021
Q2
$1.91M Buy
+9,000
New +$1.65M 0.05% 348

Other funds holding NVAX

Centiva Capital's NVAX Position: Q1 2025 in Review

Centiva Capital sold out of Novavax (NVAX) in Q1 2025, closing a stake of 11,959 shares — an estimated $96.2K sold.

Centiva Capital first reported a position in NVAX in Q1 2021 and held it in 9 quarters. The position peaked at $3.72M in Q4 2021. 246 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • Centiva Capital reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • Centiva Capital sold 11,959 Novavax shares in Q1 2025, an estimated $96.2K.
  • Centiva Capital first reported a position in Novavax in Q1 2021 and held it in 9 quarters.
  • Centiva Capital's Novavax position peaked at $3.72M in Q4 2021.
  • 246 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.